← Back to searchRecruitingRecruiting
Combination of Novel Therapies for CKD Comorbid Depression
NCT04422652 · Stony Brook University
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Combination of Novel Therapies for CKD Comorbid Depression (CONCORD)
About this study
Aim 1. Compare the efficacy and tolerability of two 16-week strategies vs. control for treatment of CKD patients with MDD starting with (1) BAT or (2) bupropion, each augmented to a combination of both in non-remitters. Primary hypothesis: Treatment with either strategy will improve depression (primary endpoint) and be tolerable.
Patients with stages 3b-5 CKD and MDD (N=201) will be randomized 1:1:1 to 16 weeks of:
Strategy 1: Single-blind BAT plus placebo, augmented in non-remitters at 8 weeks with single-blind bupropion; Strategy 2: Double-blind bupropion plus single-blind Clinical Management (CM) attention control, augmented in non-remitters at 8 weeks with single-blind BAT; Control: CM attention control plus placebo. There will be \>80% power to detect a minimal clinically important difference (MCID) of 2 points on the Quick Inventory of Depressive Symptomatology between each intervention and control, assuming a 14% attrition rate.
Exploratory aim (a): Explore if remote access to therapy via internet vs. travel to clinic affects treatment efficacy.
Aim 2. Investigate efficacy and tolerability of 8 weeks (Phase 1) of (1) BAT plus placebo or (2) bupropion plus CM, vs. control, for improvement in depression. Secondary hypothesis: Treatment with 8 weeks of BAT or bupropion will improve depression. There will be 80% power to detect a MCID of 2 points between each arm and control, assuming 10% attrition.
Exploratory aims:
(a) Investigate whether patient preference for BAT vs. drug affects treatment efficacy; (b) compare efficacy of each combination in Phase 2 with control; (c) compare change from baseline in plasma C-reactive protein in drug vs. BAT or control arms.
Aim 3. Investigate the efficacy of these two 16-week treatment strategies vs. control for improvement in CKD patient-centered outcomes including: (a) adherence to medications and healthcare visits; (b) fatigue; (c) sleep; (d) overall functioning. Secondary hypothesis: Treatment with either strategy will result in clinically meaningful improvements in adherence, fatigue, sleep and overall functioning in patients with CKD.
Eligibility criteria
Inclusion Criteria:
1. Male or female adults aged 18 years or greater. There will be no upper age limit.
2. Presence of CKD stages 3b, 4 or 5, with an estimated glomerular filtration rate (GFR) of \<45 mL/min/1.73 m2 for a period of at least 3 months, as defined by the National Kidney Foundation and determined using the four-variable Modification of Diet for Renal Diseases Study formula.
3. Presence of a current Major Depressive Disorder (MDD) based on MINI DSM IV-based criteria
4. Quick Inventory of Depressive Symptomatology-Self-report (QIDS-SR) score of ≥11 at enrollment and ≥11 on QIDS-Clinician Rated (QIDS-C) at randomization.
5. Able to understand and sign informed consent after the nature of the study has been fully explained
6. Kidney transplant patients that are at least 6 month post-transplantation (3 months post-transplant, with at least another 3 months to confirm eGFR \<45)
Exclusion Criteria:
1. Unable to understand or give informed consent.
2. Unwilling or unable to participate in the protocol or comply with any of its components
3. Significant hepatic dysfunction or liver enzyme abnormalities 3 times or greater than the upper limit of normal
4. Terminal chronic obstructive pulmonary disease or cancer
5. Presence of seizure disorder
6. Current use of class I anti-arrhythmic medications (such as 1C propafenone and flecanide), pimozide, MAO inhibitors, reserpine, guanethidine, cimetidine, or methyldopa; tri-cyclic anti-depressants, neuroleptics, or anti-convulsants
7. Use of serotonergic drugs or supplements such as triptans, tramadol, linezolid, tryptophan, and St. John's Wort.
8. Use of medications known to cause QT prolongation on EKG
9. Ongoing use of antidepressant medications for depression treatment
10. Past treatment failure on bupropion
11. Initiation of depression-focused psychotherapy in the 3 months prior to study entry
12. Active alcohol or substance abuse or dependence that requires acute detoxification at study entry
13. Present or past psychosis or Bipolar I or II disorder
14. Dementia or a Mini-Mental State Examination score \<23
15. Active suicidal intent
16. Pregnancy, lactation, or women of childbearing potential not willing to use adequate contraception
Study design
Enrollment target: 201 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2020-09-24
Estimated completion: 2027-04-01
Last updated: 2025-11-28
Interventions
Drug: BupropionBehavioral: Behavioral activation therapyDrug: PlaceboOther: Clinical Management
Primary outcomes
- • Quick Inventory of Depressive Symptomatology-Clinician Rated scale (QIDS-C) (Assessed at baseline and weeks 4, 6, 8, 12, and 16)
Sponsor
Stony Brook University · other
With: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contacts & investigators
ContactMeredith McAdams, MD · contact · Meredith.McAdams@UTSouthwestern.edu · 214-645-5418
ContactAna Arroyo · contact · ana.arroyo@utsouthwestern.edu · 214-648-8283
InvestigatorSusan Hedayati, MD · principal_investigator, Stony Brook University
All locations (4)
Stony Brook University Medical CenterNot Yet Recruiting
Stony Brook, New York, United States
Parkland Health and Hospital SystemRecruiting
Dallas, Texas, United States
UT Southwestern and AffiliatesRecruiting
Dallas, Texas, United States
University of WashingtonRecruiting
Seattle, Washington, United States